Methods for modulating immune responses
AssigneeStemnion, Inc.
InventorsRichard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
Life of this patent
Estimating the term…
Abstract
The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.
Claims5
A method for down-regulating the immune response an allogeneic graft tissue or organ exhibits when it is transplanted into a subject, the method comprising the step of simultaneously transplanting the allogeneic graft tissue or organ and a purified population of CD 117-negative Amnion-derived Multipotent Progenitor (AMP) cells into the subject such that the AMP cells down-regulate the immune response exhibited by the allogeneic graft tissue or organ.
A method for improving engraftment of an allogeneic graft tissue or organ that is transplanted into a subject in need thereof, the method comprising the step of simultaneously transplanting the allogeneic graft tissue or organ and a purified population of CD117-negative AMP cells into the subject such that the AMP cells down-regulate a GVHD response following the transplantation such that improved engraftment of the allogeneic graft tissue or organ results.
Dependencies are inferred from the claim text.